Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 11/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.45 |
| ▸ | HTR1D | P28221 | 5/20 | 0.41 |
| ▸ | HTR1B | P28222 | 4/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3726001 | 0.99 | ADRA1A (0.44) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| Methane SCHEMBL3662291 | 0.87 | RAD52 (0.43) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL4986530 | 0.87 | ADRA1A (0.50) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL12304316 | 0.86 | HTR1D (0.41) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL4992395 | 0.85 | HTR1D (0.50) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL14092049 | 0.84 | HTR1D (0.49) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL5200810 | 0.83 | TAAR1 (0.51) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| Hydrochloric Acid SCHEMBL5203153 | 0.82 | TAAR1 (0.50) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL4983426 | 0.82 | ADRA1A (0.45) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL2381264 | 0.79 | HTR1D (0.43) | ADRA1AADRA1DADRA1BADRA2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237639-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ROCHE PALO ALTO LLC. | 2011-09-29 | — | — | US | claimed |
| US-20110237639-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ROCHE PALO ALTO LLC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237639-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ROCHE PALO ALTO LLC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237639-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ROCHE PALO ALTO LLC. | 2011-09-29 | — | — | US | disclosed |
| CN-101925582-A | N- [ 3-bromo-2-chloro-4- (4, 5-dihydro-1H-imidazol-2-ylmethyl) -phenyl ] -methanesulfonamide as alpha-1A adrenergic partial agonist for the treatment of incontinence | HOFFMANN LA ROCHE | 2010-12-22 | — | — | CN | disclosed |
| EP-2238113-A1 | N-[3-BROMO-2-CHLORO-4-(4, 5-DIHYDRO-1H-IMIDAZOL-2-YLMETHYL)-PHENYL] -METHANESULFOAMIDE AS ALPHA-1 A ADRENERGIC PARTIAL AGONIST FOR THE TREATMENT OF INCONTINENCE | F. Hoffmann-La Roche AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| EP-2238113-A1 | N-[3-BROMO-2-CHLORO-4-(4, 5-DIHYDRO-1H-IMIDAZOL-2-YLMETHYL)-PHENYL] -METHANESULFOAMIDE AS ALPHA-1 A ADRENERGIC PARTIAL AGONIST FOR THE TREATMENT OF INCONTINENCE | F. Hoffmann-La Roche AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009098134-A1 | N-[3-BROMO-2-CHLORO-4-(4, 5-DIHYDRO-1H-IMIDAZOL-2-YLMETHYL)-PHENYL] -METHANESULFOAMIDE AS ALPHA-1 A ADRENERGIC PARTIAL AGONIST FOR THE TREATMENT OF INCONTINENCE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098134-A1 | N-[3-BROMO-2-CHLORO-4-(4, 5-DIHYDRO-1H-IMIDAZOL-2-YLMETHYL)-PHENYL] -METHANESULFOAMIDE AS ALPHA-1 A ADRENERGIC PARTIAL AGONIST FOR THE TREATMENT OF INCONTINENCE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098134-A1 | N-[3-BROMO-2-CHLORO-4-(4, 5-DIHYDRO-1H-IMIDAZOL-2-YLMETHYL)-PHENYL] -METHANESULFOAMIDE AS ALPHA-1 A ADRENERGIC PARTIAL AGONIST FOR THE TREATMENT OF INCONTINENCE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197932-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ROCHE PALO ALTO LLC | 2009-08-06 | — | — | US | disclosed |
| US-20090197932-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ROCHE PALO ALTO LLC | 2009-08-06 | — | — | US | disclosed |
| US-20090197932-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ROCHE PALO ALTO LLC | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237639-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ADRA1A, ADRA1D, ADRB1 | ADRA1A 1/4885ADRA1D 2/4885ADRA1B 4/4885 |
| US-20090197932-A1 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE | ADRA1A, ADRA2A, ADRA1D | ADRA1A 1/4885ADRA1D 3/4885ADRA1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.